Yuichiro Ohe
Université Paris-Sud
2 papers in the Anchorcite directory, published between 2009 and 2017, cited 13,995 times in total.
ORCID profileResearch topics
- Lung Cancer Diagnosis and Treatment · 2 papers
- Lung Cancer Treatments and Mutations · 2 papers
- Lung Cancer Research Studies · 1 paper
- HER2/EGFR in Cancer Research · 1 paper
Frequent co-authors
- Busayamas Chewaskulyong · 2 papers
- Tony S.K. Mok · 1 paper
- Yi-Long Lung Cancer Wu · 1 paper
- Sumitra Thongprasert · 1 paper
- Da-Tong Chu · 1 paper
- Nagahiro Saijo · 1 paper
- Patrapim Sunpaweravong · 1 paper
- Baohui Han · 1 paper
Papers
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine · 2009 · 8,355 citations
BACKGROUND: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer. METHODS: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced…
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 5,640 citations
BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell…
Metadata from OpenAlex (CC0).